Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

A technology of pulmonary fibrosis and liposome preparation, applied in the field of nebulizer and lung administration, which can solve the problems of unclear pulmonary fibrosis

Inactive Publication Date: 2015-07-01
GALECTO BIOTECH
View PDF17 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Mechanisms leading to pulmonary fibrosis are unclear, but focus on abnormal wound healing due to repeated epithelial injury for still unknown reasons

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
  • Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis
  • Galactoside inhibitor of galectin-3 and its use for treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0145] Compounds of formula (I) can be prepared as described in the experimental part below.

[0146] Therefore, there is provided a method for preparing a compound of formula I, comprising the steps of: making bis-(3-deoxy-3-azido-β-D-galactopyranosyl)sulfane with 3-fluorophenylacetylene and Reaction of an amine such as triethylamine, optionally in the presence of a catalyst such as Cu(I), in a solvent such as N,N-dimethylformamide (DMF) affords compounds of formula I. In a particular embodiment there is provided a process for the preparation of a compound of Formula I comprising the steps as described in Scheme 1 of the Experimental Section. Furthermore, the present invention relates to compounds of formula (I) obtainable by combining bis-(3-deoxy-3-azido-β-D-galactopyranosyl)sulfane with 3-fluorobenzene Reaction of an acetylene and an amine such as triethylamine, optionally in the presence of a catalyst such as Cu(I), in a solvent such as N,N-dimethylformamide (DMF) afford...

Embodiment 1

[0215] Example 1 Measuring Galectin-3 Levels in Human Lung Biopsies:

[0216] Biopsies were sampled from patients with Usual Interstitial Pneumonia (UIP, the most common cause of IPF). Biopsies were fixed in neutral buffered formalin for 12-24 h before embedding in solid paraffin for sectioning. Sections of 5um were cut and transferred to glass slides. Sections were deparaffinized in xylene for 10 min and rehydrated by placing slides in graded ethanol (100%-95%-80%-70%-50%-water) for 2 min each. Antigen retrieval was performed by microwave sectioning in 0.01 M citric acid pH 6.0 for 15 min. After cooling in running tap water, peroxidase was blocked by incubation in 1% hydrogen peroxide solution for 15 min. Slides were rinsed in phosphate-buffered saline (PBS), and non-specific binding was blocked using serum-free protein blocking and an avidin / biotin blocking kit (Vector Laboratories, USA). Sections were incubated overnight at 4°C with mouse monoclonal anti-human galectin-...

Embodiment 2

[0220] Example 2 Method for Measuring Galectin-3 Levels in Human Serum or Human Bronchoalveolar Lavage Fluid:

[0221] 1. Dilute the capture antibody to a working concentration in PBS without carrier protein. Immediately coat a 96-well microplate with 100 μL / well of diluted capture antibody. The plate was sealed and incubated overnight at room temperature.

[0222] 2. Aspirate wells and wash with wash buffer, repeat this process twice for a total of three washes. Wash by filling each well with wash buffer (400 μL) using a spray bottle, manifold dispenser, or automatic detergent. Complete removal of liquid at each step is essential for good performance. After the last wash, remove any residual wash buffer by aspirating or by inverting the plate and blotting with a clean paper towel.

[0223] 3. Block the plate by adding 300 [mu]L of reagent dilution to each well. Incubate at room temperature for at least 1 hour.

[0224] 4. Repeat the aspiration / washing as in step 2. The...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a compound of the general formula (I) for pulmonary administration. The compound of formula (I) is suitable for treating pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a mammal. Furthermore the present invention concerns a method for treatment of pulmonary fibrosis, such as Idiopathic pulmonary fibrosis in a human subject.

Description

technical field [0001] The present invention relates to novel compounds, the use of said compounds as medicaments and for the manufacture of medicaments for the treatment of pulmonary fibrosis, such as idiopathic pulmonary fibrosis in mammals. The invention also relates to pharmaceutical compositions comprising said novel compounds. In addition, the present invention relates to pulmonary administration, in particular the use of a nebulizer to provide an optimized treatment of IPF. Background technique [0002] Idiopathic pulmonary fibrosis (IPF) represents a huge global health burden. It is a chronic disease of unknown etiology in which repeated acute lung injuries cause progressive fibrosis, which leads to destruction of the lung structure, deterioration of lung function and consequent respiratory failure and death. Although idiopathic pulmonary fibrosis (IPF) is archetypal and the most common cause of pulmonary fibrosis, numerous respiratory diseases can develop into pul...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/70A61K9/00A61M11/00A61M15/00A61K31/7056A61P11/00
CPCA61K9/0075A61K9/0078A61K31/70A61K31/7056A61M11/005A61M15/0065A61M15/0085A61M2202/064A61M15/001A61P11/00A61P43/00
Inventor 乌尔夫·尼尔松哈康·莱弗勒尼尔·亨德森塔里克·塞蒂艾利森·麦金农
Owner GALECTO BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com